CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor1
Aug 17, 2022Neurodevelopmental Disorder Therapy1

Top competitors of Anavex Life Sciences

Top competitors of Anavex Life Sciences based on patent oppositions.